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BACKGROUND: Short-term variability of the QT interval (STVQT) has been proposed as a novel electrophysiological marker for 
the prediction of imminent ventricular arrhythmias in animal models. Our aim is to study whether STVQT can predict imminent 
ventricular arrhythmias in patients.
METHODS AND RESULTS: In 2331 patients with primary prophylactic implantable cardioverter defibrillators, 24-hour ECG Holter 
recordings were obtained as part of the EU-CERT-ICD (European Comparative Effectiveness Research to Assess the Use of 
Primary Prophylactic Implantable Cardioverter Defibrillators) study. ECG Holter recordings showing ventricular arrhythmias of 
>4 consecutive complexes were selected for the arrhythmic groups (n=170), whereas a control group was randomly selected 









, where Dn represents the QT interval. STVQT was determined before the ventricular arrhythmia or 
8:00 am in the control group and between 1:30 and 4:30 am as baseline. STVQT at baseline was 0.84±0.47 ms and increased 
to 1.18±0.74 ms (P<0.05) before the ventricular arrhythmia, whereas the STVQT in the control group remained unchanged. The 
arrhythmic patients were divided into three groups based on the severity of the arrhythmia: (1) nonsustained ventricular ar-
rhythmia (n=32), (2) nonsustained ventricular tachycardia (n=134), (3) sustained ventricular tachycardia (n=4). STVQT increased 
before nonsustained ventricular arrhythmia, nonsustained ventricular tachycardia, and sustained ventricular tachycardia from 
0.80±0.43 ms to 1.18±0.78 ms (P<0.05), from 0.90±0.49 ms to 1.14±0.70 ms (P<0.05), and from 1.05±0.22 ms to 2.33±1.25 ms 
(P<0.05). This rise in STVQT was significantly higher in sustained ventricular tachycardia compared with nonsustained ven-
tricular arrhythmia (+1.28±1.05 ms versus +0.24±0.57 ms [P<0.05]) and compared with nonsustained ventricular arrhythmia 
(+0.34±0.87 ms [P<0.05]).
CONCLUSIONS: STVQT increases before imminent ventricular arrhythmias in patients, and the extent of the increase is associ-
ated with the severity of the ventricular arrhythmia.
Key Words: short-term variability of repolarization ■ ventricular arrhythmia ■ ventricular tachycardia
Treatment of ventricular arrhythmias and prevention of sudden cardiac death (SCD) rapidly evolved in the past century, and innovations continuously 
contribute to further improvement. Introduction of the 
implantable cardioverter defibrillator (ICD) reduced the 
mortality rate in patients with a high risk for SCD.1–3 
Nevertheless, SCD remains an important healthcare 
concern, and research about underlying mechanisms 
Correspondence to: Marc A. Vos, PhD, Alexander Numan Building 4th Floor, Yalelaan 50, 3584 CM, Utrecht, The Netherlands. E-mail: m.a.vos@umcutrecht.nl
For Sources of Funding and Disclosures, see page 8.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use 
is non-commercial and no modifications or adaptations are made. 




 http://ahajournals.org by on M
arch 3, 2021
J Am Heart Assoc. 2020;9:e018133. DOI: 10.1161/JAHA.120.018133 2
Smoczyńska et al STV Predicts Ventricular Arrhythmia
and novel treatments is ongoing.4 Temporal disper-
sion of repolarization, quantified as short-term variabil-
ity (STV), has been identified as a promising marker 
for arrhythmic risk monitoring. In animal models, STV 
at baseline discriminated between subjects that de-
veloped ventricular arrhythmias or SCD in the long 
term.5–7 Similar results were obtained in patients with 
acquired8 or congenital9 long-QT syndrome, patients 
with nonischemic heart failure,10 and patients with 
structural heart disease,11 where an elevated STV at 
baseline was associated with patients with a history of 
ventricular arrhythmias or the occurrence of ventricu-
lar arrhythmias during follow-up. A novel application of 
STV, being the ability to predict imminent ventricular 
arrhythmias, has also been studied preclinically. In an-
imal studies, STV increases abruptly before ventricular 
arrhythmias, whereas it remains stable in the absence 
of arrhythmic events.6,12,13 Moreover, STV is a suitable 
parameter to guide preventive therapy to avert the im-
mediate (re)occurrence of ventricular arrhythmias.14 
We aim to investigate whether STV of the QT interval 
(STVQT) also increases before ventricular arrhythmias in 
patients and could therefore be used to predict immi-
nent ventricular arrhythmias in a clinical setting.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Design
The EU-CERT-ICD (European Comparative Effec-
tiveness Research to Assess the Use of Primary 
Prophylactic Implantable Cardioverter Defibrillators) 
is a prospective multicenter, observational study.15 It 
aims to assess the current clinical value of the ICD 
in patients with primary prophylaxis and the electro-
cardiographic parameters at baseline for long-term 
prediction of all-cause mortality and appropriate ICD 
shocks. Patients with ischemic and nonischemic 
cardiomyopathy fulfilling the international treatment 
guidelines for primary prophylactic ICD implantation 
were included.16 The protocol was approved by the in-
stitutional review board or ethics committee at each 
participating hospital and was in compliance with the 
Declaration of Helsinki. All patients provided written 
informed consent. A 12-lead Holter ECG (CM 3000-
12 BT; Getemed, Teltow, Germany) was recorded at 
1 kHz sampling frequency for 24 hours in hospitalized 
patients before the ICD implantation. Holter recordings 
showing ventricular arrhythmias of >4 consecutive 
complexes were selected. A control group was ran-
domly selected from the remaining Holter recordings 
not fulfilling this criterion.
Measurement of STVQT and other 
electrophysiological parameters
Precordial lead V2 or V3 was selected in each patient 
based on the morphology of the T-wave. The precordial 
lead with the highest amplitude and slope at the end of 
the T-wave was used for the determination of the RR 
and QT intervals and for the calculation of STVQT. QTc 
was calculated according to the Framingham formula. 








, where D represents 
the determinant of repolarization (in this case the QT 
interval), and N represents the number of beats taken 
into account −1.12 The change in STVQT between base-
line and before ventricular arrhythmia was calculated 
CLINICAL PERSPECTIVE
What Is New?
• In patients with primary prophylactic implant-
able cardioverter defibrillators, an increase in 
temporal dispersion of repolarization, quantified 
as short-term variability of the QT interval, pre-
cedes ventricular arrhythmias.
• The extent of the increase in short-term vari-
ability of the QT interval is associated with the 
severity of the ventricular arrhythmia.
What Are the Clinical Implications?
• Temporal dispersion of repolarization is a prom-
ising parameter for monitoring imminent ven-
tricular arrhythmias.
Nonstandard Abbreviations and Acronyms
∆STVQT STVQT beforeventricular 
arrhythmia minus STVQT at 
baseline
EU-CERT-ICD European Comparative 
Effectiveness Research to 
Assess the Use of Primary 
Prophylactic Implantable 
Cardioverter Defibrillators
nsVA nonsustained ventricular 
arrhythmia
nsVT nonsustained ventricular 
tachycardia
SCD sudden cardiac death
STV short-term variability
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as ∆STVQT=STVQT of the last 31 complexes before ven-
tricular arrhythmia – STVQT baseline. All electrophysi-
ological parameters were determined at baseline and 
before the longest ventricular arrhythmia exhibited by 
a patient or at 8:00 am in the control group. The latter 
time point was chosen because the circadian pattern 
of STVQT shows the highest peak at 8:00  am, espe-
cially in patients with a high burden of ventricular ec-
topy and nonsustained ventricular tachycardia (nsVT).17 
Baseline measurements were performed at 3:00  am 
unless a ventricular arrhythmia occurred, then base-
line was determined at a time point at least 1.5 hours 
away from the ventricular arrhythmia but between 1:30 
and 4:30 am (Figure 1A). In addition to the STV of the 
final 31 complexes preceding the ventricular arrhyth-
mia, STV was also determined on the 32 to 62 and 63 
to 93 prior complexes to follow the behavior of STV 
before the arrhythmic event (Figure  1B). Ventricular 
and atrial premature complexes together with the pre-
ceding and following post–extrasystolic beat were ex-
cluded from analysis. We used the method of fiducial 
segment averaging for the measurement of the QT 
interval and calculation of STVQT.
18 First, all complexes 
were aligned around a trigger point, in this case the 
R-peak of the QRS complex by cross-correlating each 
individual complex with the average of the remainder 
complexes and then shifting the complex until maxi-
mum correlation was obtained (Figure 1CI). Next, the 
same alignment process was repeated for the 2 other 
fiducial points, QRS onset and the end of the T-wave, 
respectively (Figure  1CII and III). Correct alignment 
was checked visually and adjusted manually where 
necessary.
Statistical Analysis
Numeric data are expressed as mean±SD unless 
specified otherwise. One-way analysis of variance 
(ANOVA) with Tukey correction for multiple com-
parisons was used for group analyses, and for the 
comparisons to baseline within a group, 1-way re-
peated-measures ANOVA with Tukey correction was 
applied. Group comparisons with both within-subject 
and between-subject variables were performed with a 
Figure 1. Study methodology.
Short-term variability of the QT interval was determined twice in every patient: baseline at 3:00 am unless a ventricular arrhythmia 
occurred, then the baseline was determined at a time point at least 1.5 hours away from the ventricular arrhythmia but between 
1:30 and 4:30 am (A) and before the ventricular arrhythmia the short-term variability of the QT interval was determined in the last 31 
preceding complexes (B). To monitor the behavior of short-term variability of the QT interval before the ventricular arrhythmia, 2 more 
segments of 31 complexes were used for the determination of short-term variability of the QT interval, namely, the segments of 62 to 
32 and 93 to 63 preceding complexes. The method of fiducial segment averaging was applied to determine the QT interval as the sum 
of the QR interval and the RT interval (C). (I) All complexes were aligned at the R peak as the trigger point. (II) The complexes were 
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2-way ANOVA with Tukey correction for multiple com-
parisons. Categorical variables were analyzed with a 
χ2 test. Calculations were performed using SPSS (ver-
sion 26; IBM, Armonk, NY) and Prism (version 8.0; 
GraphPad Software Inc., La Jolla, CA). P<0.05 was 
considered as statistically significant.
RESULTS
Study Population
The EU-CERT-ICD study enrolled 2292 patients from 
May 2014 until August 2018. For this substudy, we 
screened all the Holter ECG recordings, and 455 pa-
tients showed ventricular arrhythmias of >4 consecu-
tive complexes (Figure  2). A total of 285 Holter ECG 
recordings were excluded from analysis, for example, 
because of atrial arrhythmias (n=106), excessive noise 
(n=30), a flat T-wave (n=40), or excessive ectopy result-
ing in<31 consecutive beats (n=24). The remaining 170 
Holter ECG recordings were suitable for analysis. A va-
riety of ventricular arrhythmias occurred in the study 
population; therefore, the patients were divided into 3 
groups based on the severity of the arrhythmia. The 
first group consisted of short-lasting (<30  seconds) 
ventricular arrhythmias of <100 beats per minute (bpm) 
defined as nonsustained ventricular arrhythmia (nsVA) 
(n=32). The second group showed short-lasting ven-
tricular tachy-arrhythmias of ≥100 bpm defined as nsVT 
(n=134). The third group were longer lasting (≥30 sec-
onds) ventricular tachy-arrhythmias of ≥100 bpm de-
fined as sustained ventricular tachycardia (VT) (n=4). 
The control group consisted of 37 patients.
Table 1 shows clinical baseline characteristics of the 
patients included in the analysis. The VT group was 
excluded from statistical analysis as a subgroup be-
cause of the missing values in an already low num-
ber of patients. There were no statistical differences 
in baseline characteristics between the overall group 
with ventricular arrhythmias and the control group, nor 
were there statistical differences between patients with 
nsVA and nsVT. The mean age of patients with ven-
tricular arrhythmias was 63±11 years and 60±12 years 
in the control group. The study population was pre-
dominantly male, and the majority of the patients had 
ischemic cardiomyopathy as the leading cardiac dis-
ease, with 57% in the overall group with ventricular ar-
rhythmias and 70% in the control group. Medication 
use was similar in the overall group with ventricular ar-
rhythmias and the control group. In the group with a 
VT, 33% used ß-blockers.
Arrhythmia Characteristics
Ventricular arrhythmias occurred throughout the day, 
as illustrated in Figure 3. nsVA tended to occur from 
late afternoon (5:00 pm) until early morning (7:00 am), 
whereas nsVTs were distributed throughout the entire 
Figure 2. Study flow chart.
The 24-hour Holter ECG recordings containing ventricular arrhythmias with > 4 consecutive beats were selected. After exclusion 
of recordings rendered unsuitable for analysis, short-term variability of repolarization was measured before the longest arrhythmic 
episode in each of the remaining 170 patients. The patients were subdivided into 3 groups based on the duration and heart rate of the 
ventricular arrhythmia. bpm indicates beats per minute.
24-hour Holter ECG recordings
n = 2331
Recordings containing a ventricular 
arrhythmia of >4 consecuve complexes
n = 455















<30 seconds >30 seconds
<100 bpm >100 bpm >100 bpm
Exclusion
n = 285
- Atrial arrhythmia (n = 106)
- Excessive noise (n = 30)
- Flat T-wave (n = 40)
- <31 consecuve beats remaining due to ectopy (n = 24)
- Other (e.g. corrupt/ missing files) (n = 85)
Recordings without a ventricular arrhythmia 
of >4 consecuve complexes
n = 1876
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day with a peak at 10:00 pm. The VTs occurred in the 
morning between 6:00 and 7:00 am, and in the early 
evening between 5:00 and 7:00 pm. The mean heart 
rate of all ventricular arrhythmias was 127±30 bpm, 
82±12 bpm during nsVA, 136±22 bpm during nsVT, 
and 177±26 during VT. The duration of ventricular 
arrhythmias overall was 5±6  seconds, nsVA lasted 
for 5±4 seconds, nsVT lasted for 4±3 seconds, and 
VT lasted for 39±2  seconds. The number of com-
plexes during the ventricular arrhythmia was 12±18 
in general, nsVA lasted for 8±5 complexes, nsVT 
lasted for 10±6 complexes, and VT lasted for 116±12 
complexes.
Electrophysiological Parameters
Table  2 summarizes the electrophysiological param-
eters at baseline and before the ventricular arrhythmia. 
At baseline, no significant differences were observed 
between the groups for the RR, QT, and QTc intervals 
and STVQT. Overall, the heart rate before the ventricular 
arrhythmias was significantly higher than the heart rate 
Table 1. Patient Characteristics at Baseline
Control, n=37 Overall VA, n=170 nsVA, n=32 nsVT, n=134 VT, n=4
Age, y 60±12 63±11 66±13 63±11 59±12
Sex (male) 28 (76) 147 (87) 30 (94) 116 (87) 1 (100)
Leading cardiac disease
I-CMP 26 (70) 96 (57) 21 (66) 74 (56) 1 (33)
NI-CMP 11 (30) 72 (43) 11 (34) 59 (43) 2 (67)
LVEF (%) 29±5 27±6 28±6 27±6 29±4
Smoking 21 (57) 110 (66) 18 (56) 91 (68) 1 (33)
Diabetes mellitus 9 (24) 46 (27) 7 (22) 37 (28) 2 (67)
Hypertension 19 (51) 99 (59) 23 (72) 74 (56) 2 (67)
β-blocker 37 (100) 156 (93) 30 (94) 125 (94) 1 (33)
ACEi/ARB 26 (70) 129 (77) 21 (66) 105 (79) 3 (100)
MRA 28 (76) 132 (79) 26 (81) 104 (78) 2 (67)
Statin 26 (70) 115 (69) 22 (69) 91 (68) 2 (67)
Class I or III 
antiarrhythmic drugs
1 (3) 1 (0.6) 0 (0) 1 (0.6) 0 (0)
Data are expressed as mean±SD or as number (percentage). ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; 
I-CMP, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NI-CMP, nonischemic cardiomyopathy; 
nsVA, nonsustained ventricular arrhythmia; nsVT, nonsustained ventricular tachycardia; VA, ventricular arrhythmia; and VT, sustained ventricular tachycardia.
No statistically significant differences were found. Missing values for sex: 3 in the VT group; for other characteristics: 1 in the nsVT group and 1 in the VT 
group.
Figure 3. Diurnal distribution of ventricular arrhythmia occurrence.
The number of patients exhibiting their longest ventricular arrhythmia during 1 day. Four patients had 
VT, which were clustered in the morning (6:00–7:00 am) and early evening (5:00–7:00 pm). nsVA indicates 
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in baseline, with the exception of patients exhibiting 
nsVA. The QT and QTc intervals were shorter before 
nsVT and VT compared with baseline, but were the 
same before nsVA and their respective baseline val-
ues. In the control group there were no differences in 
the RR, QT, and QTc intervals between 3:00  am and 
8:00 am.
STVQT Increases Before Ventricular 
Arrhythmias
The behavior of STVQT before a ventricular arrhythmia 
compared with baseline is shown in Figure 4. STVQT 
did not change in the control group between 3:00 am 
and 8:00  am, from 0.75±0.23  ms to 0.82±0.26  ms, 
respectively. STVQT increased significantly before 
nsVA and nsVT, from 0.80±0.43  ms at baseline to 
1.18±0.78  ms in the last 31 complexes before nsVA 
and from 0.90±0.49  ms at baseline to 1.14±0.70  ms 
in the last 31 complexes before nsVT. The increase in 
STVQT was most pronounced in patients with VT, from 
1.05±0.22 ms at baseline to 2.32±1.25 ms in the last 
31 complexes before VT. This observation was con-
firmed by comparing the ∆STVQT between the groups, 
whereby ∆STVQT was significantly higher in VT com-
pared with nsVT (+1.28±1.05 ms versus +0.24±0.57 ms), 
compared with nsVA (+0.34±0.87 ms), and compared 
with the control group (+0.07±0.18 ms). The STVQT in-
creased progressively during the segments preceding 
the ventricular arrhythmia, as portrayed in Figure 4c. 
Compared with baseline, STVQT was increased in the 
segment of 62 to 32 beats onward before ventricular 
Table 2. Electrophysiological Parameters
Control, n=37 Overall VA, n=170 nsVA, n=32 nsVT, n=134 VT, n=4
Baseline
RR interval 1013±129 979±166 1009±155 972±170 972.0±128.6
QT interval 441±45 427±44 426±42 427±44 412±32
QTc interval 439±39 446±46 424±32 432±34 414±39
STVQT 0.75±0.23 0.84±0.47 0.80±0.43 0.90±0.49 1.05±0.22
Before VA (last 31 complexes)
RR interval 967±141 929±152* 1008±132 914±150*,‡ 769±137*,‡
QT interval 429±51 412±49* 427±40 409±51* 384±36*
QTc interval 434±42 429±43* 425±30 422±44* 415±16
STVQT 0.82±0.26 1.18±0.74*,† 1.18±0.78*,† 1.14±0.70*,† 2.33±1.25*,†
Data are expressed as mean±SD in milliseconds. nsVA indicates nonsustained ventricular arrhythmia; nsVT, nonsustained ventricular tachycardia; STVQT, 
short-term variability of the QT interval; VA, ventricular arrhythmia; and VT, sustained ventricular tachycardia.
*P<0.05 compared with baseline within the group.
†P<0.05 compared with control group.
‡P<0.05 compared with nsVA.
Figure 4. Behavior of STVQT before ventricular arrhythmia.
A, STVQT of the last 31 complexes increases before a ventricular arrhythmia. Data are expressed as mean±SD. B, ∆STVQT is higher 
before VT than nsVA and nsVT. Data are expressed as mean±SD. C, STVQT is increased from the segment 62 to 32 complexes 
before a ventricular arrhythmia and onward. Data are expressed as mean±SEM. *P<0.05 within-group comparison; †P<0.05 between-
group comparison. ∆STVQT indicates STVQT before ventricular arrhythmia minus STVQT at baseline; nsVA, nonsustained ventricular 
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arrhythmia. This translates to approximately 60 to 
30 seconds before the ventricular arrhythmia based on 
the mean heart rate of 65 bpm (RR interval of 929±152; 
Table  2). STVQT was stable in the segments around 
8:00  am in the control group and continuously lower 
than the overall group with ventricular arrhythmias.
DISCUSSION
The results of the current study in patients with pri-
mary prophylactic ICD can be summarized as follows: 
(1) temporal dispersion of repolarization quantified as 
STVQT increases before ventricular arrhythmias com-
pared with baseline conditions; (2) in the absence of 
ventricular arrhythmias, STVQT remains stable between 
baseline conditions at 3:00 am and at 8:00 am; (3) the 
increase in STVQT progresses during the minutes pre-
ceding a ventricular arrhythmia and is significantly 
higher from the segment of 62 to 32 beats before 
the ventricular arrhythmia and onward; and (4) STVQT 
increases more before VT compared with nsVA and 
nsVT, when it is expressed as ∆STVQT.
Increase in Temporal Dispersion of 
Repolarization Reflects a Compromised 
Repolarization Reserve
To our knowledge, this is the first study showing that an 
increased temporal dispersion of repolarization, quan-
tified as STVQT, precedes the imminent occurrence of 
ventricular arrhythmias in patients with primary prophy-
lactic ICD. In animal models, the importance of tempo-
ral dispersion of repolarization in arrhythmogenesis has 
been studied extensively.6,12,19 Ventricular remodeling 
attributed to volume overload in the canine model of 
complete chronic atrioventricular block includes elec-
trical (downregulation of the slowly (IKs) and rapidly (IKr) 
activating delayed rectifier potassium channels),20 con-
tractile (altered calcium handling),21–24 and structural 
remodeling.25 Electrical remodeling results in a dimin-
ished repolarization reserve, which renders the heart 
unable to withstand stressors on repolarization.25 This 
repolarization lability manifests itself as a prolongation 
of repolarization duration and an increased temporal 
dispersion of repolarization.6,12 When repolarization 
is challenged further by, for example, an IKr-blocking 
drug, this can act as a final hit on the repolarization 
reserve.26 In combination with the altered calcium 
handling this gives rise to early afterdepolarizations in 
vitro12,21 and ventricular ectopy and Torsade de Pointes 
arrhythmias in vivo.12,27 These arrhythmias are pre-
ceded by an increase in STV, whereas STV remains 
low in nonsusceptible subjects.12,13 Moreover, the se-
verity of the arrhythmic outcome in the chronic atrio-
ventricular block dog is also correlated to the ∆STV, as 
in this patient population.28 The current study suggests 
that a reduced repolarization reserve and triggered 
activity play a role in arrhythmogenesis in a broad pa-
tient population with both ischemic and nonischemic 
cardiomyopathy.
Proarrhythmic Component of STVQT That 
Is Independent of the QT-Interval Duration
Although STVQT is based on QT-interval measure-
ments, these parameters show a different circadian 
rhythm and behave differently before ventricular ar-
rhythmias. The circadian rhythm of the QT interval 
has a cosine curve with a longer QT interval at night 
around 3 am and a shorter QT interval in the afternoon 
around 2:00 pm.29 This has been attributed to diurnal 
changes in potassium ion channel function.30 Similarly, 
the QT interval of our current study was the longest at 
baseline, between 1:30 and 4:30  am. STVQT also ex-
hibits a circadian pattern in patients with a higher bur-
den of ventricular ectopy and nsVT, whereby there is a 
peak in STVQT at 8:00 am and 6:00 pm.
17 These peaks 
coincide with the circadian distribution of SCD31 and 
are consistent with the occurrence of VT in our study 
population. It has been hypothesized that the circa-
dian pattern of STVQT relies on the autonomic nervous 
system.17,32 Interestingly, both peaks of STVQT coincide 
with the maximum slope in the diurnal cosine curve of 
the QT interval, suggesting that these are 2 different, 
yet potentially related, parameters.
Moreover, our finding that STVQT increases before 
ventricular arrhythmias without prolongation of the QT 
interval contributes to the hypothesis that there is an in-
dependent proarrhythmic component responsible for 
an increase in STVQT. The QT interval is a well-known 
and broadly applied electrophysiological parameter 
for proarrhythmic assessment. However, preclinical 
studies in different animal models indicate that STV 
is superior to the repolarization duration in predicting 
the development of imminent ventricular arrhythmias 
and assessing the efficacy of antiarrhythmic inter-
ventions.19,33 In the chronic atrioventricular block dog 
model, repolarization duration prolonged upon a chal-
lenge of the repolarization irrespective of the arrhyth-
mic outcome, whereas STV only increased in subjects 
that were susceptible for ventricular arrhythmias.6,12
Clinical Implications
Preclinical studies have demonstrated that STV can 
be used to monitor the risk for imminent ventricular 
arrhythmias and initiate a preventive treatment.14,34 
This study shows that STV has a similar behavior be-
fore ventricular arrhythmias in patients with a primary 
prophylactic indication for ICD therapy. Currently, pa-
tients at risk for ventricular arrhythmias and SCD are 
implanted with an ICD. Although the ICD can success-




 http://ahajournals.org by on M
arch 3, 2021
J Am Heart Assoc. 2020;9:e018133. DOI: 10.1161/JAHA.120.018133 8
Smoczyńska et al STV Predicts Ventricular Arrhythmia
pacing or a defibrillation shock, the ICD is not able yet 
to prevent the arrhythmias from occurring. The detri-
mental effects of ventricular arrhythmias and the re-
duced quality of life as a result of anxiety for shock 
therapy give cause to seek further improvement of 
the ICD.35 STV can be derived reliably from electro-
gram signals that are continuously recorded by the 
ICD.13 Therefore, the ICD could be used for continu-
ous monitoring of arrhythmic risk by measuring STV 
on intracardiac signals. A preventive therapy has also 
been explored in the chronic atrioventricular block dog 
model in the form of temporary accelerated pacing, 
where the pacing rate was gradually increased from 
60 to 100 bpm in 20 seconds, and successfully pre-
vented an electrical storm from occurring in 70% of the 
cases.14 Our study shows that the increase in STVQT in 
patients is present in the segment 60 to 30 seconds 
before the ventricular arrhythmia, which provides suf-
ficient time to initiate the preventive therapy. To imple-
ment this methodology, STV should be determined 
automatically by the device and the pacing regimen 
initiated once a certain threshold of STV is reached.
Strengths and Limitations
STV determination requires accurate measurement of 
the QT interval because of the unit of the variation. This 
requirement was addressed in two ways. First, the 24-
hour ECG Holter recordings had a high resolution of 
1 kHz. Second, measurement of the QT interval was 
done with a validated semiautomated program to mini-
mize errors in measurement.17
The present study also has limitations. The number 
of patients with a VT is limited because ECG Holter 
recordings were recorded for only 24  hours in pa-
tients without a history of VT. The results in the VT 
group should therefore be interpreted with caution. 
More patients with VT can be studied when STV is 
monitored continuously with an implanted device for a 
longer period of time. It is also evident that STV can-
not be measured reliably in patients with an irregular 
heart rate attributed to, for example, atrial fibrillation. 
Furthermore, STV measurements are influenced by 
the quality of the signals; therefore, many patients 
were excluded because of noise. When the intracar-
diac electrogram can be used for STV analysis, rea-
sons for exclusion in the current study, such as noise 
and a flat T-wave, would be minor issues, and approx-
imately three quarters of the patients would be eligible 
for STV analysis.
CONCLUSIONS
This is the first clinical work to demonstrate that STVQT 
increases before imminent ventricular arrhythmias in 
patients with a primary prophylactic ICD indication and 
that the extent of the increase is associated with the 
severity of the ventricular arrhythmia. These data set a 
precedent that STVQT can be used for imminent ven-
tricular arrhythmia risk monitoring.
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